PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli

Core Insights - PharmAla Biotech Holdings Inc. has signed an advisory agreement with Matthew Azrieli, a current shareholder, to enhance its market presence and clinical trials business in the United States and other growth markets [1][2] - The advisory agreement includes up to 1 million Performance Share Units contingent on achieving specific corporate goals in media advisory, market development, and investment advisory [2] - PharmAla is focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, and aims to alleviate the global backlog of clinical-grade MDMA for trials and commercial sales [3] Company Overview - PharmAla Biotech is the only company currently providing clinical-grade MDMA for patient treatments outside of clinical trials [3] - The company has completed proof-of-concept research into several intellectual property families, including its lead drug candidate ALA-002 [3] - PharmAla operates under a "regulatory first" principle, emphasizing strong relationships with regulators to succeed in the psychedelics industry [3] Upcoming Events - PharmAla will host a webinar on February 6, 2025, at 4:30 PM ET to discuss its financial results and future plans [3]